Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,963 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Open enrollment, early-phase tilt
Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.
- 423
- recruiting participants now
- 34%
- of trials open to enrollment
- 120
- in Phase 3-4 (later-stage)
- 98
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 10 of 26
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
AstraZeneca
NCT05629585
Social Risk Factors and Discrimination in Cancer Survivorship
Medstar Health Research Institute
NCT05301114
Cone Beam Breast CT for Breast Cancer Screening
Koning Corporation
NCT05036096
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
Memorial Sloan Kettering Cancer Center
NCT01134172
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
AstraZeneca
NCT05113251
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
Dana-Farber Cancer Institute
NCT03070236
Johns Hopkins Breast Cancer Program Longitudinal Repository
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01937039
Menstrual Cycle Maintenance and Quality of Life: A Prospective Study
Memorial Sloan Kettering Cancer Center
NCT00589654
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
Dana-Farber Cancer Institute
NCT05629065
Genetic Risk Estimations for Influencing Decision Making in Women at High Risk of Breast Cancer, GENRE 2 Study
Mayo Clinic
NCT04474834
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
AstraZeneca
NCT00099437
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
NCT05104866
Improving Care After Inherited Cancer Testing
Vanderbilt-Ingram Cancer Center
NCT04763915
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
AstraZeneca
NCT04644068
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Celcuity
NCT05501886
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
City of Hope Medical Center
NCT01472094
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
University of Colorado, Denver
NCT05838417
Relaxation for Women With Breast Cancer Undergoing Radiotherapy
M.D. Anderson Cancer Center
NCT01202851
Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT00582478
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
AstraZeneca
NCT05374512
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
Pharmacogenomics ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
NCT06062810
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Daiichi Sankyo
NCT03734029
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Daiichi Sankyo
NCT03529110
Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Patients.
University of Colorado, Denver
NCT04739696
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
AstraZeneca
NCT04739761
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Eli Lilly and Company
NCT04188548
Long Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer
City of Hope Medical Center
NCT04661982
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
Eli Lilly and Company
NCT02246621
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Hoffmann-La Roche
NCT05646862
Understanding and Predicting Breast Cancer Events After Treatment
Wake Forest University Health Sciences
NCT02791581
Using Diagnostic Tools to Stage Breast Cancer
University of Pennsylvania
NCT00367666
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
Weill Medical College of Cornell University
NCT04175210
Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
Dana-Farber Cancer Institute
NCT03422003
Genetic Testing for All Breast Cancer Patients (GET FACTS)
Dana-Farber Cancer Institute
NCT04245176
YES Study - Newly Diagnosed/Metastatic Intervention
Dana-Farber Cancer Institute
NCT04379414
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
University of Kansas Medical Center
NCT02958774
Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
Shayna Showalter, MD
NCT02400658
A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction
Memorial Sloan Kettering Cancer Center
NCT05316324
Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
M.D. Anderson Cancer Center
NCT02263014
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
NCT04191499
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
University of Chicago
NCT00989638
Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors
Northwestern University
NCT05931874
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
Alliance for Clinical Trials in Oncology
NCT04711109
Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
NYU Langone Health
NCT02276885
Sexual Health Empowerment for Women's Health
University of Kansas Medical Center
NCT03984695
Early Detection of Breast Cancer in Women With Suspicious Mammograms
Sentara Norfolk General Hospital
NCT03147430
The Effect of Acupuncture on Cancer-Related Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
NCT04837820
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Cancer right now
423 recruiting of 1,251 indexed (34% open).
Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Breast Cancer?
PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Cancer?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.